These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
704 related articles for article (PubMed ID: 32929210)
1. Establishment of patient-derived cancer organoids for drug-screening applications. Driehuis E; Kretzschmar K; Clevers H Nat Protoc; 2020 Oct; 15(10):3380-3409. PubMed ID: 32929210 [TBL] [Abstract][Full Text] [Related]
2. High-throughput drug screening of fine-needle aspiration-derived cancer organoids. Bergdorf K; Phifer C; Bharti V; Westover D; Bauer J; Vilgelm A; Lee E; Weiss V STAR Protoc; 2020 Dec; 1(3):100212. PubMed ID: 33377106 [TBL] [Abstract][Full Text] [Related]
3. Stem cell-derived organoids and their application for medical research and patient treatment. Bartfeld S; Clevers H J Mol Med (Berl); 2017 Jul; 95(7):729-738. PubMed ID: 28391362 [TBL] [Abstract][Full Text] [Related]
4. Importance of organoids for personalized medicine. Perkhofer L; Frappart PO; Müller M; Kleger A Per Med; 2018 Nov; 15(6):461-465. PubMed ID: 30418092 [TBL] [Abstract][Full Text] [Related]
5. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. Mun SJ; Ryu JS; Lee MO; Son YS; Oh SJ; Cho HS; Son MY; Kim DS; Kim SJ; Yoo HJ; Lee HJ; Kim J; Jung CR; Chung KS; Son MJ J Hepatol; 2019 Nov; 71(5):970-985. PubMed ID: 31299272 [TBL] [Abstract][Full Text] [Related]
6. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Grassi L; Alfonsi R; Francescangeli F; Signore M; De Angelis ML; Addario A; Costantini M; Flex E; Ciolfi A; Pizzi S; Bruselles A; Pallocca M; Simone G; Haoui M; Falchi M; Milella M; Sentinelli S; Di Matteo P; Stellacci E; Gallucci M; Muto G; Tartaglia M; De Maria R; Bonci D Cell Death Dis; 2019 Feb; 10(3):201. PubMed ID: 30814510 [TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Organoids for Tumor Modeling and Drug Screening. Yehya A; Ghamlouche F; Hachem S; Abou-Kheir W Methods Mol Biol; 2024; 2777():135-144. PubMed ID: 38478341 [TBL] [Abstract][Full Text] [Related]
9. Next-Generation Modeling of Cancer Using Organoids. Love JR; Karthaus WR Cold Spring Harb Perspect Med; 2024 Jun; 14(6):. PubMed ID: 37734867 [TBL] [Abstract][Full Text] [Related]
10. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids. Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032 [TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Pasch CA; Favreau PF; Yueh AE; Babiarz CP; Gillette AA; Sharick JT; Karim MR; Nickel KP; DeZeeuw AK; Sprackling CM; Emmerich PB; DeStefanis RA; Pitera RT; Payne SN; Korkos DP; Clipson L; Walsh CM; Miller D; Carchman EH; Burkard ME; Lemmon KK; Matkowskyj KA; Newton MA; Ong IM; Bassetti MF; Kimple RJ; Skala MC; Deming DA Clin Cancer Res; 2019 Sep; 25(17):5376-5387. PubMed ID: 31175091 [TBL] [Abstract][Full Text] [Related]
12. Use and application of 3D-organoid technology. Artegiani B; Clevers H Hum Mol Genet; 2018 Aug; 27(R2):R99-R107. PubMed ID: 29796608 [TBL] [Abstract][Full Text] [Related]
13. Patient-derived cancer organoids for drug screening: Basic technology and clinical application. Ren X; Chen W; Yang Q; Li X; Xu L J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719 [TBL] [Abstract][Full Text] [Related]
14. Advance in Human Epithelial-Derived Organoids Research. Li F; Zhang P; Wu S; Yuan L; Liu Z Mol Pharm; 2021 Nov; 18(11):3931-3950. PubMed ID: 34582198 [TBL] [Abstract][Full Text] [Related]
15. The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma? Farshbaf A; Lotfi M; Zare R; Mohtasham N Pharmacogenomics J; 2023 May; 23(2-3):37-44. PubMed ID: 36347937 [TBL] [Abstract][Full Text] [Related]
16. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening. Deben C; De La Hoz EC; Compte ML; Van Schil P; Hendriks JMH; Lauwers P; Yogeswaran SK; Lardon F; Pauwels P; Van Laere S; Bogaerts A; Smits E; Vanlanduit S; Lin A Cell Oncol (Dordr); 2023 Apr; 46(2):299-314. PubMed ID: 36508089 [TBL] [Abstract][Full Text] [Related]
17. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer. Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Factors as Predictors for Establishment of Patient Derived Head and Neck Squamous Cell Carcinoma Organoids. de Kort WWB; Millen R; Driehuis E; Devriese LA; van Es RJJ; Willems SM Head Neck Pathol; 2024 Jun; 18(1):59. PubMed ID: 38940869 [TBL] [Abstract][Full Text] [Related]
19. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review). Cao J; Chan WC; Chow MSS Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860 [TBL] [Abstract][Full Text] [Related]
20. Engineering the Vasculature of Stem-Cell-Derived Liver Organoids. Zhang X; Tang L; Yi Q Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34208902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]